Search
Razuprotafib
go.drugbank.com/drugs/DB16353InvestigationalRazuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injec...
Abexinostat
go.drugbank.com/drugs/DB12565InvestigationalAbexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with p...
Astodrimer
go.drugbank.com/drugs/DB11854InvestigationalAstodrimer has been used in trials studying the treatment and prevention of Bacterial Vaginosis. It is a lysine-based dendrimer with naphthalene disulfonic acid surface groups.
Anpocogin
go.drugbank.com/drugs/DB06552InvestigationalRecombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.
POT-4
go.drugbank.com/drugs/DB06056InvestigationalPOT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). The investigational drug was under investigation in clinical trial NCT00473...
Patupilone
go.drugbank.com/drugs/DB03010InvestigationalEpothilone B is a 16-membered macrolide that mimics the biological effects of taxol.
Antithrombin III human
go.drugbank.com/drugs/DB11598ApprovedInvestigationalA plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
IL-2 pDNA
go.drugbank.com/drugs/DB05935ExperimentalVical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma.
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of the GI tract is severely impai...
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.